The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

“While assessments of medical records and registries have not suggested increased risk of suicide or self-harm with GLP-1 receptor agonist use, these data are not ideal to answer this question ...

The move comes after Novo announced disappointing results in December from a late-stage trial of a different obesity pipeline project, CagriSema, a combination of its semaglutide GLP-1 receptor ...

More Type 1 Diabetics Are Obese, Taking GLP-1 Drugs By Dennis Thompson HealthDay Reporter MONDAY, March 31, 2025 (HealthDay News) -- Use of cutting-edge weight-loss drugs like Ozempic and Zepbound ...